Dixon Hughes Goodman Wealth Advisors’s BioNTech BNTX Stock Holding History

Dixon Hughes Goodman Wealth Advisors’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$9K	Buy	+55	New	+$9.24K	﹤0.01%	527

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dixon Hughes Goodman Wealth Advisors's BNTX Position: Q1 2022 in Review

Dixon Hughes Goodman Wealth Advisors opened a new position in BioNTech (BNTX) in Q1 2022: 55 shares worth $9K. The stake represents ﹤0.01% of the portfolio and ranks #527 among its holdings.

287 funds tracked by Wall St. Rank hold BNTX as of Q1 2022.

Dixon Hughes Goodman Wealth Advisors held 55 shares of BioNTech worth $9K as of Q1 2022.
BioNTech was a new Dixon Hughes Goodman Wealth Advisors position in Q1 2022.
BioNTech made up ﹤0.01% of Dixon Hughes Goodman Wealth Advisors's portfolio in Q1 2022, its #527 holding.
287 funds tracked by Wall St. Rank held BioNTech as of Q1 2022.

Based on Dixon Hughes Goodman Wealth Advisors's 13F filing for Q1 2022, filed 4 Apr 2022.